2020
Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, Womack SJ, Hoenes AC, Zeiss C, Young LH, Spinale FG, Sinusas AJ. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC CardioOncology 2020, 2: 774-787. PMID: 33437965, PMCID: PMC7799406, DOI: 10.1016/j.jaccao.2020.09.007.Peer-Reviewed Original ResearchSac/ValRodent modelsControl animalsMMP activityMatrix metalloproteinasesAngiotensin receptor blocker therapyAngiotensin receptor-neprilysin inhibitionTime-matched control animalsMyocardial MMP activityReceptor blocker therapySacubitril/valsartanHeart failure patientsVentricular ejection fractionAnthracycline-induced cardiotoxicityDoxorubicin-Induced CardiotoxicityMale Wistar ratsSubgroup of animalsBlocker therapyAldosterone inhibitorsSystolic dysfunctionFailure patientsEjection fractionCardioprotective actionVentricular remodelingMyocardial infarction
2018
Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines
Toro-Salazar OH, Lee JH, Zellars KN, Perreault PE, Mason KC, Wang Z, Hor KN, Gillan E, Zeiss CJ, Gatti DM, Davey BT, Kutty S, Liang BT, Spinale FG. Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines. Cardio-Oncology 2018, 4: 4. PMID: 29900007, PMCID: PMC5995570, DOI: 10.1186/s40959-018-0030-5.Peer-Reviewed Original ResearchLow cumulative dosesBiomarker profilesCumulative dosesSerial cardiac magnetic resonance imagingResultsLeft ventricular ejection fractionCardiac magnetic resonance imagingAbnormal strain parametersSerum biomarker profilesAnti-inflammatory markersVentricular ejection fractionPediatric cancer survivorsPediatric cancer patientsFunctional imaging parametersPlasma biomarker profilesMagnetic resonance imagingAnthracycline doseAnthracycline dosesAnthracycline dosingLongitudinal strain magnitudeSubclinical dysfunctionAnthracycline treatmentEjection fractionPediatric patientsCancer survivorsInterleukin-10